WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services
share
- WuXi Biologics and Boostimmune have signed an MOU to collaborate on research and discovery services for Boostimmune’s anti-cancer therapies targeting the tumor immune microenvironment and novel ADCs.
- Boostimmune will leverage WuXi Biologics’ expertise in antibody discovery, lead optimization, in vitro screening, and in vivo tests. WuXi Biologics will exclusively support Boostimmune in generating various modality candidates, including monoclonal and bispecific antibodies, as well as recombinant proteins.
- The partnership aims to develop a compelling pipeline of innovative biologics to enhance patient lives, aligning with the flourishing biotech industry in South Korea and global healthcare needs.
Article Summary
WuXi Biologics and Boostimmune have announced a strategic collaboration by signing a Memorandum of Understanding (MOU) to jointly advance the field of anti-cancer therapies. WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), is set to partner with Boostimmune, a biotech company dedicated to pioneering next-generation therapies targeting the tumor immune microenvironment and developing Antibody-Drug Conjugates (ADCs) for novel targets.
This partnership holds significant promise, as Boostimmune will gain access to WuXi Biologics’ comprehensive suite of integrated discovery services. WuXi Biologics’ expertise encompasses a range of critical stages in biologics development, including antibody discovery, lead optimization, in vitro screening, and characterization, alongside in vivo testing. This collaboration designates WuXi Biologics as the exclusive service partner for facilitating the creation of diverse modality candidates, spanning monoclonal and bispecific antibodies, as well as recombinant proteins.
Dr. Gwanghee Lee, Co-founder and CEO of Boostimmune, expressed enthusiasm about the collaboration’s potential to unlock novel biological candidates and delve into the intricacies of complex proteins. He envisions this collaboration as a catalyst for establishing a robust pipeline that could profoundly enhance patient outcomes and well-being. The partnership with WuXi Biologics represents a pivotal step forward for Boostimmune’s ambitious research and development endeavors.
Dr. Chris Chen, CEO of WuXi Biologics, underscored the importance of this collaboration in fostering innovation within the biotech sector. He highlighted the vibrant growth of the biotech industry in South Korea and the mounting demand for end-to-end discovery and development services. This collaboration will not only aid Boostimmune in advancing its pioneering pipeline but also contribute to the broader mission of providing groundbreaking biologics solutions to patients globally. The partnership signifies WuXi Biologics’ commitment to supporting both local and global partners in delivering impactful therapies to the market.
In alignment with the flourishing biotech landscape in South Korea, this partnership is poised to harness collective expertise, leveraging WuXi Biologics’ technological prowess and Boostimmune’s therapeutic vision. Together, they aim to push the boundaries of cancer treatment research and elevate the standards of patient care through innovative biologic solutions.
